

Chemotherapy Induced Cognitive and Executive Impairment in Hematological Malignancies

Thesis

*Submitted for Partial Fulfillment of Master Degree
in Internal Medicine*

Presented by

Mohamed Gamal Mohamed Kotb

MBBCH

Faculty of Medicine, Ain Shams University

Under Supervision of

Prof. Abdel Rahman Abdel Hamid Soliman

Professor of Internal Medicine and Clinical Hematology

Faculty of Medicine, Ain Shams University

Dr. Rasha Ibrahim Ibrahim

***Assistant Professor of Internal Medicine and Clinical
Hematology***

Faculty of Medicine, Ain Shams University

Dr. Rasha Magdy Mohammed Said

Lecturer of Internal Medicine and Clinical Hematology

Faculty of Medicine, Ain Shams University

Faculty of Medicine - Ain Shams University

2017

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببناك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*All praise are to **AUAAH** and all thanks. He has guided and enabled me by his mercy to fulfill this thesis, which I hope to be beneficial for people.*

*I would like to express my deepest gratitude and sincere appreciation to **Prof. Dr. Abdel Rahman Abdel Hamid Soliman**, Professor of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University for his encouragement, his kind support and appreciated suggestions that guided me to accomplish this work.*

*I am also grateful to **Prof. Dr. Rasha Ibrahim Ibrahim**, Assistant Professor of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University, who freely gave her time, effort and experience along with continuous guidance throughout this work.*

*Many thanks for **Dr. Rasha Magdy Mohammed Said**, Lecturer of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University, for her sincere support.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Mohamed Gamal Mohamed Kotb

List of Contents

Title	Page No.
List of Tables	5
List of Figures	8
List of Abbreviations	10
Introduction	1
Aim of the Work.....	4
Review of Literature	
▪ Hematological Malignancy.....	5
▪ Cognitive Function.....	68
▪ Chemotherapy Adverse Effects	77
Patients and Methods	105
Results	108
Discussion	130
Summary and Conclusion	137
Recommendations	139
References	140
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Immunophenotyping of AML Cells	17
Table (2):	2016 WHO classification of AML.....	19
Table (3):	Cotswold Modification of Ann Arbor Staging System.....	40
Table (4):	Non-Hodgkin's lymphoma types	44
Table (5):	Ann Arbor staging classification for NHL	45
Table (6):	Chemotherapeutic regimens for NHL	51
Table (7):	Treatment options for cutaneous T-cell lymphoma by stage	57
Table (8):	Novel therapies for NHL	59
Table (9):	Common laboratory features of plasma cell dyscrasia	60
Table (10):	Multiple myeloma therapies	65
Table (11):	Durie-Salmon Staging System and International Staging System	66
Table (12):	Tests for cognitive impairment	99
Table (13):	Showing descriptive data about the patients of the study.....	108
Table (14):	Showing sex demonstration of the patients	109
Table (15):	Showing the number of each individual disease diagnoses of our patients.	110
Table (16):	Showing individual chemotherapy regimens received by patients included at the study.....	111
Table (17):	Showing the number of patients receiving oral and others receiving parenteral chemotherapy	112
Table (18):	Showing the number patients associated with each comorbidity	113
Table (19):	Remission status of all patients 6 month post chemotherapy at our study	114

List of Tables (Cont...)

Table No.	Title	Page No.
Table (20):	Showing Montreal test results among our patients	115
Table (21):	Showing descriptive data about each individual component of Montreal test.	116
Table (22):	Describes Comparison between patients with normal cognitive functions and patients with cognitive impairment as regards the age of the patients, number of chemotherapy cycles received, and period of hospital admission of the patients	117
Table (23):	Describes Comparison between male and female patients as regards each component of Montreal scoring system.	118
Table (24):	Describes Comparison between routes of chemotherapy administration of the patients included at the study as regards each component of Montreal scoring system	119
Table (25):	Describes the comparison between patients with disease comorbidities and patients without comorbidities as regards each component of Montreal scoring system	120
Table (26):	Describes the comparison between patients outcome 6 month post chemotherapy as regards each component of Montreal scoring system	121
Table (27):	Describes the comparison of different type of malignancy of the patients included at the study as regards component of Montreal scoring system.	122

List of Tables (Cont...)

Table No.	Title	Page No.
Table (28):	Describes comparison between different protocols of chemotherapy received by the patients included at the study as regards each component of Montreal scoring system	123
Table (29):	Describes the correlation of demographic data, nature of disorder, some comorbidities, chemotherapy received, route of administration, and follow up results after 6 months as well as any other chemotherapy induced organ toxicity for the patients included in study with the Montreal test score	124
Table (30):	Describes the correlation of the age of the patients, number of chemotherapy cycles received, and period of hospital admission of the patients included at the study with each component of Montreal scoring system	125

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Diagnostic workup of a patient with pre-B-cell acute lymphoblastic leukemia (Bone marrow aspiration)	7
Figure (2):	Peripheral smear from a patient with chronic lymphocytic leukemia	25
Figure (3):	Blood film at 1000X magnification demonstrates the whole granulocytic lineage, including an eosinophil and a basophil seen at CML.....	31
Figure (4):	A Reed-Sternberg cell in Hodgkin lymphoma Reed-Sternberg cells are large, abnormal lymphocytes that may contain more than one nucleus	35
Figure (5):	Shows the treatment strategies advocated for early-stage Hodgkin lymphoma based on current clinical data.....	42
Figure (6):	A diagram of B-cell ontogeny and lymphomagenesis.....	43
Figure (7):	Showing sex differentiation among patients included at our study	109
Figure (8):	Draws the percentage of each malignancy type among our study populations.	110
Figure (9):	Demonstrating the percentage of each chemotherapy regimen received by the patients.....	111
Figure (10):	Demonstrating the percentage difference as regards route of administration of chemotherapy.....	112
Figure (11):	Reveals the percentages of patients had comorbidities among all of our study patients.....	113

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure (12):	Demonstrating percentage of patients follow up results after 6 month of chemotherapy.....	114
Figure (13):	Demonstrates cognitive function among our patients after Montreal test assessment.....	115

List of Abbreviations

Abb.	Full term
<i>5-FU</i>	<i>5-fluorouracil</i>
<i>ALL</i>	<i>Acute lymphoblastic leukemia</i>
<i>AML</i>	<i>Acute myelogenous leukemia</i>
<i>ANCs</i>	<i>Absolute neutrophil counts</i>
<i>APL</i>	<i>Acute promyelocytic leukemia</i>
<i>ATRA</i>	<i>All-trans retinoic acid</i>
<i>BMT</i>	<i>Bone marrow transplantation</i>
<i>CALGB</i>	<i>Cancer And Leukemia Group B</i>
<i>CBC</i>	<i>Complete blood count</i>
<i>CICI</i>	<i>Chemotherapy induced cognitive impairment</i>
<i>CINV</i>	<i>Chemotherapy induced nausea and vomiting</i>
<i>CIPN</i>	<i>Chemotherapy induced peripheral neuropathy</i>
<i>CLL</i>	<i>Chronic lymphocytic leukemia</i>
<i>CML</i>	<i>Chronic myelocytic leukemia</i>
<i>CNS</i>	<i>Central nervous system</i>
<i>CR</i>	<i>Complete remission</i>
<i>CSF</i>	<i>Cerebrospinal fluid</i>
<i>CT</i>	<i>Computed tomography</i>
<i>CTX</i>	<i>Chemotherapy</i>
<i>DIC</i>	<i>Disseminated intravascular coagulation</i>
<i>EBV</i>	<i>Epstein-Barr virus</i>
<i>ECOG</i>	<i>Eastern Cooperative Oncology Group</i>
<i>EPO</i>	<i>Erythropoietin</i>
<i>ESR</i>	<i>Erythrocyte sedimentation rate</i>
<i>FDA</i>	<i>Food and Drug Administration</i>
<i>FDG-PET</i>	<i>Fluorodeoxyglucose-positron emission tomography</i>
<i>FISH</i>	<i>Fluorescence in situ hybridization</i>
<i>GI</i>	<i>Gastrointestinal</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>HBV</i>	<i>Hepatitis B virus</i>
<i>HCT</i>	<i>Hematopoietic stem cell transplantation</i>
<i>HCV</i>	<i>Hepatitis C virus</i>
<i>HIV</i>	<i>Human immunodeficiency virus</i>
<i>HL</i>	<i>Hodgkin's Lymphoma</i>
<i>HLA</i>	<i>Human leukocyte antigen</i>
<i>IL</i>	<i>Interleukin</i>
<i>LBCL</i>	<i>Large B cell lymphoma</i>
<i>LDH</i>	<i>Lactate dehydrogenase enzyme</i>
<i>MCHL</i>	<i>Mixed-cellularity Hodgkin's lymphoma</i>
<i>MDS</i>	<i>Myelodysplastic syndrome</i>
<i>MM</i>	<i>Multiple myeloma</i>
<i>MRD</i>	<i>Minimal residual disease</i>
<i>MRI</i>	<i>Magnetic resonance imaging</i>
<i>MUGA</i>	<i>Multiple gated acquisition</i>
<i>MZL</i>	<i>Marginal zone lymphoma</i>
<i>NCCN</i>	<i>National Comprehensive Cancer Network</i>
<i>NHL</i>	<i>Non-Hodgkin's Lymphoma</i>
<i>NHL</i>	<i>Non-Hodgkin's lymphoma</i>
<i>NLPHL</i>	<i>Nodular lymphocyte predominant Hodgkin's disease</i>
<i>NSHL</i>	<i>Non sclerosing Hodgkin's lymphoma</i>
<i>OS</i>	<i>Overall survival</i>
<i>PCR</i>	<i>Polymerase chain reaction</i>
<i>PET</i>	<i>Positron Emission Tomography</i>
<i>Ph</i>	<i>Philadelphia</i>
<i>RT-PCR</i>	<i>Reverse transcriptase polymerase chain reaction</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>S1P</i>	<i>Sphingosine-1-phosphate</i>
<i>SLE</i>	<i>Systemic lupus erythematosus</i>
<i>SLL</i>	<i>Small lymphocytic lymphoma</i>
<i>SWOG</i>	<i>Southwest Oncology Group</i>
<i>THRLBCL</i>	<i>T-cell histiocyte-rich large B-cell lymphoma</i>
<i>TKIs</i>	<i>Tyrosine kinase inhibitors</i>
<i>TNF</i>	<i>Tumor necrosis factor</i>
<i>TTF</i>	<i>Time to treatment failure</i>
<i>WBC</i>	<i>White blood cell count</i>
<i>WHO</i>	<i>World Health Organization</i>

INTRODUCTION

In 2015, an estimated 162, 000 new cases of hematological malignancies were diagnosed (approximately 10% of all cancer diagnoses) and over 1·8 million haematological cancer survivors live in the United States (*Howlader et al., 2014*).

Improved diagnosis and treatment have markedly increased survival for many patients with haematological malignancies. Based on the most recent literature, current 5-year survival rates are as follows: all leukaemia 60.3%, Hodgkin lymphoma (HL) 87.7% and non-HL (NHL) 71.4% (*Howlader et al., 2014*).

Nearly all leukaemias and 69% of NHL are treated with chemotherapeutic agents (*Rossi et al., 2015*).

Treatment-related side effects, including cognitive impairment, can decrease treatment compliance and ultimately impact quality of life; however, a deep understanding of the etiology of these cognitive problems as a consequence of disease and/or treatment in hematological malignancies is still in its infancy (*Wefel et al., 2004*).

Chemotherapy-induced cognitive impairment (CICI) is a collection of problems in memory, attention, concentration and executive functions that is associated with chemotherapy treatments in cancer patients. These problems can range from

subtle to severe and last for months or years after treatment (*Bradley et al., 2005*).

CRCI affects an estimated 10 million cancer survivors in the United States. Based on data from all types of cancers, up to 30% of survivors experience cognitive impairment prior to therapy, 80% during therapy, and up to 35% may live with CRCI up to 20 years after treatment (*Koppelmans et al., 2012*).

Decreased cognitive function is associated with poorer quality of life, inability to achieve work and educational goals, inability to drive or read, and decreased social connectedness (*Reid-Arndt et al., 2010*).

To date, the CICI literature is dominated by breast cancer and other solid tumours. Haematological malignancies are usually systemic, and often treated with chemotherapeutic agents that have been implicated in CICI in solid tumours. The growing literature in this area suggests that cognition is an important predictor of survival in patients with haematological malignancies and therefore, understanding factors that lead to CICI in haematological malignancies warrants attention (*Dubruille et al., 2015*).

Research on cognitive function in most types of haematological malignancies is limited. However, studies of cognitive function in paediatric acute lymphoblastic leukaemia (ALL), indicate that cognitive impairment can persist for years

after completion of treatment. Clearly, a subset of hematological malignancy survivors experience CICI (*Elisabeth et al., 2009*).

A study done 2005 on Acute Myeloid Leukemia (AML) and Myelodysplastic syndrome (MDS) patients had revealed Decline on motor function, psychomotor speed, memory, executive function post chemotherapy (*Meyers et al., 2005*).

Another study done at 2012 on Hodgkin lymphoma patients revealed worse than controls on attention, memory, executive function, processing speed post chemotherapy (*Krull et al., 2012*).